Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2909]

ASCO GI: Second-line ramucirumab added to standard chemotherapy delays disease progression, extends survival for patients with advanced colorectal cancer

ASCO GI: Second-line ramucirumab added to standard chemotherapy delays disease progression, extends survival for...

Most types of cancer not due to “bad luck”, says IARC

Most types of cancer not due to “bad luck”, says IARC

Disappointment over NHS England's bowel cancer drug decision

Disappointment over NHS England's bowel cancer drug decision

ASCO GI: Combining newer, more intensive first-line chemo with bevacizumab improves long-term outcome in advanced colorectal cancer

ASCO GI: Combining newer, more intensive first-line chemo with bevacizumab improves long-term outcome in advanced...

Screening for HPV infection alone more accurate than Pap Test in the detection of cervical cancer, especially in younger women

Screening for HPV infection alone more accurate than Pap Test in the detection of cervical cancer, especially in...

More than a third of people in the UK with abnormal results drop out of bowel cancer screening

More than a third of people in the UK with abnormal results drop out of bowel cancer screening

Statistical modelling links cancer risk with number of stem cell divisions

Statistical modelling links cancer risk with number of stem cell divisions

SABCS 2014: Multigene test can predict risk of disease recurrence for women with ductal carcinoma in situ

SABCS 2014: Multigene test can predict risk of disease recurrence for women with ductal carcinoma in situ

Genes that cause pancreatic cancer identified by new tool that spots cancerous changes invisible to sequencing

Genes that cause pancreatic cancer identified by new tool that spots cancerous changes invisible to sequencing

ASH 2014: Phase II trial shows maintenance with ixazomib in newly diagnosed multiple myeloma may be feasible

ASH 2014: Phase II trial shows maintenance with ixazomib in newly diagnosed multiple myeloma may be feasible

More from ecancer